Cabotegravir or CAB LA is a game-changing medicine in preventing HIV and is the most effective form of PrEP ((pre-exposure prophylaxis) currently available to people at high risk of HIV.

However, today there are many barriers for people to access CAB LA. The lack of transparency around the pricing and registration plans of the drug, unnecessary delays over agreeing a voluntary license, and implementation-science conditions have all acted as barriers to access to this injectable medicine, particularly in low- and middle-income countries (LMICs).

MSF’s Access Campaign is working in a variety of ways to try to open up equitable access to CAB LA that could prevent potentially millions of additional HIV cases.

In these personal testimonies from Eswatini, we hear from Tholakele Madlala and Lindokuhle Dlamini about how an injectable form of PrEP such as CAB LA could protect them better from HIV infection, we also hear from Nqobile Mmema, a Qualitative Research Assistant with MSF in Eswatini, more broadly about the need for more choice for ways people can protect themselves from HIV infection.